The advent of sodium-glucose co-transporter 2 (SGLT2) inhibitors has marked a significant milestone in the treatment of diabetes, offering multifaceted benefits beyond glycemic control. Amongst these inhibitors, Dapagliflozin stands out for its potential to impact not only blood sugar levels but also crucially influence kidney and heart health. Diabetes, a chronic metabolic disorder, often presents a dual challenge by being a major risk factor for both chronic kidney disease (CKD) and cardiovascular complications.
Understanding the effects of Dapagliflozin on kidney and heart events in individuals grappling with diabetes and CKD is essential for refining treatment approaches and elevating overall health outcomes. This examination aims to unravel the intricate mechanisms and clinical significance of Dapagliflozin, spotlighting its capacity to alleviate the burden of diabetic complications on these vital organs.
